Accepted for Publication: August 21, 2020.
Corresponding Author: Jonathan A. C. Sterne, MA, MSc, PhD, Department of Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, England (firstname.lastname@example.org).
Published Online: September 2, 2020. doi:10.1001/jama.2020.17023
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group Authors and Members of the Writing Committee: Jonathan A. C. Sterne, MA, MSc, PhD; Srinivas Murthy, MD, MSc; Janet V. Diaz, MD; Arthur S. Slutsky, CM, MD; Jesús Villar, MD, PhD; Derek C. Angus, MD, MPH; Djillali Annane, MD, PhD; Luciano Cesar Pontes Azevedo, MD, PhD; Otavio Berwanger, MD, PhD; Alexandre B. Cavalcanti, MD, PhD; Pierre-Francois Dequin, MD, PhD; Bin Du, MD; Jonathan Emberson, PhD; David Fisher, MSc; Bruno Giraudeau, PhD; Anthony C. Gordon, MBBS, MD; Anders Granholm, MD; Cameron Green, MSc; Richard Haynes, DM; Nicholas Heming, MD, PhD; Julian P. T. Higgins, BA, PhD; Peter Horby, PhD; Peter Jüni, MD; Martin J. Landray, PhD; Amelie Le Gouge, MSc; Marie Leclerc, MSc; Wei Shen Lim, BMedSci, BMBS, DM; Flávia R. Machado, MD, PhD; Colin McArthur, MBChB; Ferhat Meziani, MD, PhD; Morten Hylander Møller, MD, PhD; Anders Perner, MD, PhD; Marie Warrer Petersen, MD; Jelena Savović, BPharm, MSc, PhD; Bruno Tomazini, MD; Viviane C. Veiga, MD, PhD; Steve Webb, MBBS, MPH, PhD; John C. Marshall, MD.
Affiliations of The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group Authors and Members of the Writing Committee: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England (Sterne, Higgins, Savović); NIHR Bristol Biomedical Research Centre, Bristol, England (Sterne, Higgins); Department of Pediatrics, University of British Columbia, Vancouver, Canada (Murthy); Clinical Unit, Health Emergencies Programme, World Health Organization, Geneva, Switzerland (Diaz); Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael’s Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada (Slutsky, Jüni); Research Unit, Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain (Villar); CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain (Villar); Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (Angus); Department of Intensive Care, Raymond Poincaré Hospital (APHP), School of Medicine Simone Veil, University Paris Saclay-UVSQ, Paris, France (Annane, Heming); Hospital Sírio-Libanês, São Paulo, Brazil (Azevedo, Tomazini); Emergency Medicine Department, University of São Paulo School of Medicine, São Paulo, Brazil (Azevedo); Academic Research Organization, Hospital Israelita Albert Einstein, São Paulo, Brazil (Berwanger); HCor Research Insitute, São Paulo, Brazil (Cavalcanti); Médecine Intensive-Réanimation, INSERM CIC1415, CHRU de Tours, Tours, France (Dequin); CRICS-TriGGERSep Network, Centre d’Etude des Pathologies Respiratoires, Université de Tours, Tours, France (Dequin); Peking Union Medical College Hospital, Beijing, China (Du); Nuffield Department of Population Health, University of Oxford, Oxford, England (Emberson, Haynes, Landray); MRC Population Health Research Unit, University of Oxford, Oxford, England (Emberson, Haynes, Landray); MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, Faculty of Population Health Sciences, University College London, London, England (Fisher); CIC INSERM 1415-CHRU de Tours, Tours, France (Giraudeau, Le Gouge, Leclerc); Division of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, London, England (Gordon); Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Granholm, Møller, Perner, Petersen); Australian and New Zealand Intensive Care Research Centre, School of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (Green, McArthur, Webb); NIHR Applied Research Collaboration West, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, England (Higgins, Savović); Nuffield Department of Medicine, University of Oxford, Oxford, England (Horby); NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, England (Landray); Respiratory Medicine Department, Nottingham University Hospitals NHS Trust, Nottingham, England (Lim); Anesthesiology, Pain, and Intensive Care Department, Federal University of São Paulo, São Paulo, Brazil (Machado); Department of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand (McArthur); Hôpitaux Universitaires de Strasbourg, Service de Médecine Intensive Réanimation, Nouvel Hôpital Civil, Strasbourg, France (Meziani); INSERM UMR 1260, Regenerative Nanomedicine, FMTS, Strasbourg, France (Meziani); Department of Surgery, School of Medicine, University of São Paulo, São Paulo, Brazil (Tomazini); BP-A Beneficência Portuguesa de São Paulo, São Paulo, Brazil (Veiga); St John of God Healthcare, Subiaco, Australia (Webb); Li Ka Shing Knowledge Institute, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada (Marshall).
Author Contributions: Dr Sterne had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Sterne, Murthy, Diaz, Slutsky, Villar, Angus, Annane, Du, Gordon, Higgins, Jüni, Le Gouge, Leclerc, Machado, Møller, Perner, Tomazini, Veiga, Marshall.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Sterne, Murthy, Diaz, Villar, Angus, Fisher, Higgins, Machado, Møller, Veiga, Marshall.
Critical revision of the manuscript for important intellectual content: Sterne, Murthy, Diaz, Slutsky, Villar, Angus, Annane, Azevedo, Berwanger, Du, Cavalcanti, Dequin, Emberson, Giraudeau, Gordon, Granholm, Green, Haynes, Heming, Higgins, Horby, Jüni, Landray, Le Gouge, Leclerc, Lim, Machado, McArthur, Meziani, Møller, Perner, Petersen, Savovic, Tomazini, Veiga, Webb, Marshall.
Statistical analysis: Sterne, Murthy, Angus, Du, Emberson, Fisher, Higgins, Jüni, Møller, Perner.
Obtained funding: Gordon, McArthur, Perner, Webb.
Administrative, technical, or material support: Sterne, Murthy, Diaz, Slutsky, Villar, Angus, Du, Gordon, McArthur, Perner, Tomazini, Veiga, Webb, Marshall.
Supervision: Sterne, Murthy, Diaz, Villar, Angus, Azevedo, Machado, Meziani, Veiga, Marshall.
Conflict of Interest Disclosures: Dr Sterne reported receiving grants from the UK National Institute for Health Research (NIHR). Dr Murthy reported receiving grants from the Canadian Institutes of Health Research. Dr Slutsky reported being a co-primary investigator of one of the trials that is included in the meta-analysis. Dr Angus reported receiving personal fees from Ferring Pharmaceuticals Inc, Bristol-Myers Squibb, Bayer AG, and Alung Technologies Inc; and having patents pending for Selepressin (compounds, compositions, and methods for treating sepsis) and for proteomic biomarkers of sepsis in elderly patients. Dr Annane reported receiving grants from the French Ministry of Health; and being on the steering committees for 2 of the trials (CAPE COVID and REMAP-CAP) included in this meta-analysis. Dr Azevedo reported receiving grants from Ache Pharma; and receiving personal fees from Pfizer and Halex-Istar. Dr Berwanger reported receiving grants from AstraZeneca, Servier, Novartis, Bayer, Boehringer-Ingelheim, and Amgen. Dr Cavalcanti reported receiving grants from Bayer, Bactiguard, Johnson & Johnson do Brasil, Hemaclear, Hillrom, and Pfizer. Dr Dequin reported receiving grants from the French Ministry of Health, Abionic, Atox Bio, Sphingotec Gmbh, Adrenomed, Medspace, Aridis, Merck, Combioxin, GlaxoSmithKline, Medimmune, Genentech, Revimmune, Faron, Kenta, and Tigenix. Dr Du reported receiving grants from Peking Union Medical College, the Chinese Academy of Medical Sciences, and the Chinese Ministry of Science and Technology. Dr Emberson reported receiving grants from Boehringer Ingelheim. Dr Gordon reported receiving grants from the NIHR; receiving a research professorship from the NIHR; receiving nonfinancial support from the NIHR Clinical Research Network and the NIHR Imperial Biomedical Research Centre; receiving personal fees from GlaxoSmithKline and Bristol-Myers Squibb; and being the UK chief investigator and a member of the international trial steering committee for the REMAP-CAP trial. Dr Granholm reported receiving grants from the Novo Nordisk Foundation, Pfizer, the Rigshospitalet Research Council, Ferring Pharmaceuticals, and Fresenius Kabi; and being a member of the management committee of one of the trials (COVID STEROID) included in this meta-analysis. Dr Jüni reported receiving personal fees from Amgen, Ava, and Fresenius; receiving grants from the Canadian Institutes of Health Research and Appili Therapeutics; and serving as an unpaid member of the steering group of trials funded by Abbott Vascular, AstraZeneca, Biotronik, Biosensors, St Jude Medical, Terumo, and the Medicines Company. Dr Landray reported receiving grants from UK Research and Innovation, the UK NIHR, Health Data Research UK, the NIHR Oxford Biomedical Research Centre, MRC Population Health Research Unit, Merck, Sharp & Dohme, Novartis, Boehringer Ingelheim, the Medicines Company, and UK Biobank Ltd; and receiving nonfinancial support from Roche and AbbVie. Dr Lim reported receiving grants from Pfizer. Dr Machado reported receiving personal fees from ACHE. Dr McArthur reported receiving grants from the Health Research Council of New Zealand. Dr Perner reported receiving grants from the Novo Nordisk Foundation and Pfizer. Dr Petersen reported receiving grants from the Novo Nordisk Foundation and Pfizer. Dr Savović reported receiving grants from the UK NIHR. Dr Webb reported receiving grants from the National Health and Medical Research Council and the Minderoo Foundation. Dr Marshall reported receiving personal fees from AM Pharma; and serving as co-chair on the WHO Working Group on Clinical Characterization and as management chair for the International Forum for Acute Care Trialists. No other disclosures were reported.
Funding/Support: Funding for administrative and communications support was provided by the World Health Organization.
Role of the Funder/Sponsor: The World Health Organization (WHO) contributed to the design and conduct of the study by convening the WHO COVID-19 Clinical Management and Characterization Working Group. This group assembled information on ongoing trials and invited trial investigators to participate in this prospective meta-analysis. The WHO chief scientist invited trial investigators to participate and provided a secure portal for submission of data. Other than the contributions of Dr Diaz as a coauthor, the WHO had no role in the preparation, review, or approval of the manuscript. The WHO had no role in the decision to submit the manuscript for publication.
Disclaimer: The views expressed in this article are those of the authors and not necessarily those of the UK National Institute for Health Research or the UK Department of Health and Social Care. Dr Angus is Associate Editor, JAMA, but was not involved in any of the decisions regarding review of the manuscript or its acceptance.
Additional Contributions: We gratefully acknowledge the efforts of all trial investigators (the lists of names appear in the Supplement) and the patients who provided consent for participation. We thank Agnes Sagfors, PhD, and other staff at the W2O Group for searches of trial registries and for administrative and communications support. We thank Kerry Barot, BA (University of Bristol), for administrative support. We thank Vanderson de Souza Sampaio, PhD (Fundação de Medicina Tropical Dr Heitor Vieira Dourado-FMT-HVD, Manaus, Amazonas, Brazil; Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil; and Fundação de Vigilância em Saúde, Manaus, Amazonas, Brazil), and colleagues for providing additional data from the Metcovid trial. None of these persons received compensation beyond their usual salaries.
D , Bellissant
E , Bollaert
et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults. JAMA
. 2009;301(22):2362-2375.PubMedGoogle ScholarCrossref
D , Bellissant
E , Bollaert
et al. Corticosteroids for treating sepsis in children and adults. Cochrane Database Syst Rev
. 2019;12:CD002243.PubMedGoogle Scholar
CD , Millar
JE , Baillie
JK . Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet
. 2020;395(10223):473-475.PubMedGoogle ScholarCrossref
J , Confalonieri
M , Pastores
SM , Meduri
GU . Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019. Crit Care Explor
. 2020;2(4):e0111.PubMedGoogle Scholar
P , Lim
WS , Emberson
et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med
. Published online July 17, 2020. doi:10.1056/NEJMoa2021436PubMedGoogle Scholar
VM , Rubenfeld
GD , Thompson
et al. Acute respiratory distress syndrome: the Berlin definition. JAMA
. 2012;307(23):2526-2533.PubMedGoogle Scholar
PF , Heming
N , Meziani
et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA
. Published online September 2, 2020. doi:10.1001/jama.2020.16761Google Scholar
JAC , Savović
J , Page
et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ
. 2019;366:l4898.PubMedGoogle ScholarCrossref
GH , Oxman
AD , Vist
et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ
. 2008;336(7650):924-926.PubMedGoogle ScholarCrossref
D , Pastores
SM , Rochwerg
et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I). Intensive Care Med
. 2017;43(12):1751-1763.PubMedGoogle ScholarCrossref
D , Higgins
JPT , Simmonds
M . Comparative performance of heterogeneity variance estimators in meta-analysis. Res Synth Methods
. 2017;8(2):181-198.PubMedGoogle ScholarCrossref
J , Knapp
G . A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med
. 2001;20(24):3875-3889.PubMedGoogle ScholarCrossref
J , Ioannidis
JP , Borm
GF . The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol
. 2014;14:25.PubMedGoogle ScholarCrossref
DJ , Carpenter
JR , Morris
TP , Freeman
SC , Tierney
JF . Meta-analytical methods to identify who benefits most from treatments. BMJ
. 2017;356:j573.PubMedGoogle ScholarCrossref
DC , Berry
S , Lewis
et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) study. Ann Am Thorac Soc
. 2020;17(7):879-891.PubMedGoogle ScholarCrossref
The Writing Committee for the REMAP-CAP Investigators. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 Corticosteroid Domain randomized clinical trial. JAMA
. Published online September 2, 2020. doi:10.1001/jama.2020.17022Google Scholar
BM , Maia
IS , Cavalcanti
et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA
. Published online September 2, 2020. doi:10.1001/jama.2020.17021Google Scholar
CMP , Farias
MEL , Val
et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid). Clin Infect Dis
. Published online August 12, 2020. doi:10.1093/cid/ciaa1177
AB , Harrison
EM , Green
et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. BMJ
. 2020;369:m1985.PubMedGoogle ScholarCrossref
SM , Ahmed Ali
S , Mantfardo
B , Basu
B . Rate of intensive care unit admission and outcomes among patients with coronavirus. PLoS One
. 2020;15(7):e0235653.PubMedGoogle Scholar
LE , Rodrigo
C , Leonardi-Bee
et al. Corticosteroids as adjunctive therapy in the treatment of influenza. Crit Care Med
. 2020;48(2):e98-e106.PubMedGoogle ScholarCrossref